CARDIFF ONCOLOGY, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
CARDIFF ONCOLOGY, INC. (CRDF) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2026-02-24
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2025 was 0.00%.
- CARDIFF ONCOLOGY, INC. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-02-24 |
| 2024-12-31 | 0.00% 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |